Efficacy and Tolerability of Telmisartan/Amlodipine plus Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study
Efficacy and Tolerability of Telmisartan/Amlodipine plus Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study
复制标题
DOI：
10.1016/j.clinthera.2017.11.006
复制
发表时间：
2018-01-01
影响因子：
3.2
通讯作者：
Kim, Hyo-Soo
中科院分区：
文献类型：
--
作者：
Sung, Ki-Chul;Oh, Yong-Seog;Kim, Hyo-Soo
目的：这项为期8周的研究在韩国的目的是评估的疗效和耐受性的替米沙坦/氨氯噻嗪+氢氯噻嗪（TAH）组合与替米沙坦/氨氯噻嗪（TA）组合在原发性高血压患者，没有适当的4周治疗与TA.Methods：所有符合纳入标准的患者接受TA（40/5毫克）在为期4周的运行期（第1期）。符合原发性高血压标准的患者（平均坐位收缩压[MSSBP]，≥ 140和≥ 130，
Purpose: This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA.Methods: All patients who met the inclusion criteria received TA (40/5 mg) during a 4-week run-in period (period 1). Patients who met the criteria for essential hypertension (mean sitting systolic blood pressure [MSSBP], >= 140 and = 130 and